Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| RH01986 | Other Identifier | GSK |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study assessed the efficacy of three dry mouth products (including an experimental Oralbalance gel, oral rinse, and moisturizing spray) to relieve the feeling of dry mouth compared to water, in dry mouth population over a period of 28 days.
This was a multi-centered (two-sites), examiner-blinded, four treatment arms, stratified (by Modified Dry Mouth Inventory [DMI] score), randomized, parallel group study in participants with self-reported dry mouth symptoms as determined by participant responses to the DMI. Participants used their assigned dry mouth treatment at home for 28 days.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| OralBalance moisturizing gel | Experimental | All the participants in this arm used an experimental Oralbalance gel as instructed under the supervision of trained site staff on their visits. |
|
| Oral rinse | Experimental | All the participants in this arm used an Oral rinse as instructed under the supervision of trained site staff on their visits. |
|
| Moisturizing mouth spray | Experimental | All the participants in this arm used a moisturising mouth spray as instructed under the supervision of trained site staff on their visits. |
|
| Water only use | Sham Comparator | All the participants in this arm used water as instructed under the supervision of trained site staff on their visits. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Experimental Oralbalance Moisturizing Gel | Device | Participants placed approximately a half inch length of the gel onto the tongue and spread thoroughly using their tongue. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily. |
| Measure | Description | Time Frame |
|---|---|---|
| Modified Product Performance and Attributes Questionnaire I (PPAQ I) (Question Number 1: Relieving the Discomfort of Dry Mouth) | Participants were asked to use the following scale to rate question 1 (Relieving the discomfort of dry mouth) of PPAQ I as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. PPAQ I was assessed at 2 hours after supervised product use on Day 29 of treatment. | At Day 29 of treatment (2 hours after supervised product use) |
| Measure | Description | Time Frame |
|---|---|---|
| Modified Product Performance and Attributes Questionnaire I (PPAQ I) (Question Number 1:Relieving the Discomfort of Dry Mouth ) at Day 29 | Participants were asked to use the following scale to rate question 1 (Relieving the discomfort of dry mouth) of PPAQ I as it applied to the study product:1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. PPAQ I was assessed at 30 minutes, 1 hour, and 4 hours after supervised product use on Day 29 of treatment. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
467 participants were screened, out of which 45 were not randomized to the study. 15 did not meet study criteria, 8 were lost to follow-up, 19 withdrew their consent, and 3 were due to other reason (not specified). 422 were enrolled in the study out of which 26 did not meet eligibility criteria. Remaining 396 started the study.
Participants were recruited from 2 sites in United States of America.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | OralBalance Moisturizing Gel | All the participants in this arm used an experimental Oralbalance gel as instructed under the supervision of trained site staff on their visits. |
| FG001 | Oral Rinse | All the participants in this arm used an Oral rinse as instructed under the supervision of trained site staff on their visits. |
| FG002 | Moisturizing Mouth Spray | All the participants in this arm used a moisturising mouth spray as instructed under the supervision of trained site staff on their visits. |
| FG003 | Water Only Use | All the participants in this arm used water as instructed under the supervision of trained site staff on their visits. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | OralBalance Moisturizing Gel | All the participants in this arm used an experimental Oralbalance gel as instructed under the supervision of trained site staff on their visits. |
| BG001 | Oral Rinse |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Geometric Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Modified Product Performance and Attributes Questionnaire I (PPAQ I) (Question Number 1: Relieving the Discomfort of Dry Mouth) | Participants were asked to use the following scale to rate question 1 (Relieving the discomfort of dry mouth) of PPAQ I as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. PPAQ I was assessed at 2 hours after supervised product use on Day 29 of treatment. | Intent to treat (ITT, N= 396) population defined as all randomized participants with at least one post-baseline assessment of efficacy. The ITT population was analyzed as per randomized treatment. Number of participants analyzed for this endpoint were part of the IIT population, evaluated on Day 29. | Posted | Mean | Standard Deviation | Score on scale | At Day 29 of treatment (2 hours after supervised product use) |
|
Approximately 29 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | OralBalance Moisturizing Gel | All the participants in this arm used an experimental Oralbalance gel as instructed under the supervision of trained site staff on their visits. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| CARDIAC ARREST | Cardiac disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| BASAL CELL CARCINOMA | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| GSK Response Center | GlaxoSmithKline | 866-435-7343 | GSKClinicalSupportHD@gsk.com |
Not provided
| ID | Term |
|---|---|
| D014987 | Xerostomia |
| ID | Term |
|---|---|
| D012466 | Salivary Gland Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D014867 | Water |
| ID | Term |
|---|---|
| D006878 | Hydroxides |
| D000468 | Alkalies |
| D007287 | Inorganic Chemicals |
| D000838 | Anions |
| D007477 |
Not provided
Not provided
Not provided
Not provided
Not provided
The examiner and site staff reviewing the efficacy assessments were blinded to the treatment allocation of participants. All other study personnel (study statistician, data management staff and other employees of the Sponsor who may influence study outcomes) were blinded to the study treatments.
|
| Biotene Original Oral Rinse | Device | Participants rinsed their mouth with 15 milliliters (mL) of oral rinse for 30 seconds and spat out. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily. |
|
| Biotene Moisturizing Mouth Spray | Device | Participants sprayed one jet directly into their mouth. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily. |
|
| Water | Other | Participants were allowed to take only one measured sip of water (15 mL) 30 minutes before the supervised product use. After the supervised treatment at the site, participants assigned to the water only treatment were allowed to sip water as often as required. |
|
| At Day 29 of treatment (30 minutes, 1 hour and 4 hours after supervised product use) |
| Modified Product Performance and Attributes Questionnaire I (PPAQ I) Question Number 1: Relieving the Discomfort of Dry Mouth) Day 1 | Participants were asked to use the following scale to rate question 1 (Relieving the discomfort of dry mouth) of PPAQ I as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. PPAQ I was assessed at 30 minutes, 1 hour, 2, and 4 hours after supervised product use on Day 1 of treatment. | At Day 1 of treatment (30 minutes, 1 hour, 2 and 4 hours after supervised product use) |
| Individual Scores of All Question From 2-12 of Modified Product Performance and Attributes Questionnaire I (PPAQ I) | Participants were asked to use the following scale to rate question (Q) 2 to 12 of PPAQ I as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. PPAQ I had following questions Q2: Feeling comfortable in the mouth, Q3: Soothing your mouth, Q4: Allowing you to speak without difficulty, Q5: Effectively moistens your mouth, Q6: Effectively lubricates your mouth, Q7: Helping to freshen your breath, Q8: Protecting your mouth from drying out, Q9: Providing whole mouth comfort, Q10: Helping you to swallow without difficulty, Q11: Helping mouth feel 'normal', Q12: Having a cooling sensation. PPAQ I was assessed at 30 minutes, 1 hour, 2, and 4 hours after supervised product use on Day 1 and 29 of treatment. Individual score for each question at different tome point was reported for this endpoint. | At Day 1 and 29 (30 minutes, 1 hour, 2 and 4 hours after supervised product use) |
| Individual Scores for All Questions of Modified Product Performance and Attributes Questionnaire I (PPAQ I) at Day 8 | Participants were asked to use the following scale to rate questions of PPAQ I as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. PPAQI had following questions Q1: Relieving the discomfort of dry mouth Q2: Feeling comfortable in the mouth, Q3: Soothing your mouth, Q4: Allowing you to speak without difficulty, Q5: Effectively moistens your mouth, Q6: Effectively lubricates your mouth, Q7: Helping to freshen your breath, Q8: Protecting your mouth from drying out, Q9: Providing whole mouth comfort, Q10: Helping you to swallow without difficulty, Q11: Helping mouth feel 'normal', Q12: Having a cooling sensation. PPAQ I was assessed at 2 hours after supervised product use on Day 8 of treatment. | At Day 8 (2 hours after supervised product use) |
| Individual Questions Scores of Modified Product Performance and Attributes Questionnaire II (PPAQ II) | Participants were asked to use the following scale to rate questions of PPAQ II as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. PPAQ II had following questions; Q1: Providing relief all night, Q2: Reducing the number of times you wake up from dry mouth, Q3: Feeling less parched when you wake up, Q4: Having a long lasting dry mouth relief, Q5. Having a long lasting lubricating effect, Q6: Having a long lasting moisturizing effect. PPAQ II was assessed before supervised product use on Day 8 and 29 of treatment. | At Day 8 and 29 |
| Area Under Curve (AUC) up to 4 Hours After Treatment- Response of All Question of the Modified Product Performance and Attributes Questionnaire I (PPAQ I) | The AUC was calculated for the interval starting at the time of the 30 minute response and ending at the time of the last valid reading using the trapezoidal method on Day 1 and Day 29. AUC was calculated for the score of the individual question of PPAQ1. All the questions were scored using the following scale: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. | At Day 1 and 29 |
| Other (Withdrawal of consent) |
|
| Other (Not specified) |
|
All the participants in this arm used an Oral rinse as instructed under the supervision of trained site staff on their visits.
| BG002 | Moisturizing Mouth Spray | All the participants in this arm used a moisturising mouth spray as instructed under the supervision of trained site staff on their visits. |
| BG003 | Water Only Use | All the participants in this arm used water as instructed under the supervision of trained site staff on their visits. |
| BG004 | Total | Total of all reporting groups |
| Standard Deviation |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| OG001 | Oral Rinse | All the participants in this arm used an Oral rinse as instructed under the supervision of trained site staff on their visits. |
| OG002 | Moisturizing Mouth Spray | All the participants in this arm used a moisturising mouth spray as instructed under the supervision of trained site staff on their visits. |
| OG003 | Water Only Use | All the participants in this arm used water as instructed under the supervision of trained site staff on their visits. |
|
|
|
| Secondary | Modified Product Performance and Attributes Questionnaire I (PPAQ I) (Question Number 1:Relieving the Discomfort of Dry Mouth ) at Day 29 | Participants were asked to use the following scale to rate question 1 (Relieving the discomfort of dry mouth) of PPAQ I as it applied to the study product:1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. PPAQ I was assessed at 30 minutes, 1 hour, and 4 hours after supervised product use on Day 29 of treatment. | ITT (N= 396) population defined as all randomized participants with at least one post-baseline assessment of efficacy. The ITT population was analyzed as per randomized treatment. | Posted | Mean | Standard Deviation | Score on scale | At Day 29 of treatment (30 minutes, 1 hour and 4 hours after supervised product use) |
|
|
|
| Secondary | Modified Product Performance and Attributes Questionnaire I (PPAQ I) Question Number 1: Relieving the Discomfort of Dry Mouth) Day 1 | Participants were asked to use the following scale to rate question 1 (Relieving the discomfort of dry mouth) of PPAQ I as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. PPAQ I was assessed at 30 minutes, 1 hour, 2, and 4 hours after supervised product use on Day 1 of treatment. | ITT (N= 396) population defined as all randomized participants with at least one post-baseline assessment of efficacy. The ITT population was analyzed as per randomized treatment. | Posted | Mean | Standard Deviation | Score on scale | At Day 1 of treatment (30 minutes, 1 hour, 2 and 4 hours after supervised product use) |
|
|
|
| Secondary | Individual Scores of All Question From 2-12 of Modified Product Performance and Attributes Questionnaire I (PPAQ I) | Participants were asked to use the following scale to rate question (Q) 2 to 12 of PPAQ I as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. PPAQ I had following questions Q2: Feeling comfortable in the mouth, Q3: Soothing your mouth, Q4: Allowing you to speak without difficulty, Q5: Effectively moistens your mouth, Q6: Effectively lubricates your mouth, Q7: Helping to freshen your breath, Q8: Protecting your mouth from drying out, Q9: Providing whole mouth comfort, Q10: Helping you to swallow without difficulty, Q11: Helping mouth feel 'normal', Q12: Having a cooling sensation. PPAQ I was assessed at 30 minutes, 1 hour, 2, and 4 hours after supervised product use on Day 1 and 29 of treatment. Individual score for each question at different tome point was reported for this endpoint. | ITT(N= 396) population defined as all randomized participants with at least one post-baseline assessment of efficacy. The ITT population was analyzed as per randomized treatment. | Posted | Mean | Standard Deviation | Score on scale | At Day 1 and 29 (30 minutes, 1 hour, 2 and 4 hours after supervised product use) |
|
|
|
| Secondary | Individual Scores for All Questions of Modified Product Performance and Attributes Questionnaire I (PPAQ I) at Day 8 | Participants were asked to use the following scale to rate questions of PPAQ I as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. PPAQI had following questions Q1: Relieving the discomfort of dry mouth Q2: Feeling comfortable in the mouth, Q3: Soothing your mouth, Q4: Allowing you to speak without difficulty, Q5: Effectively moistens your mouth, Q6: Effectively lubricates your mouth, Q7: Helping to freshen your breath, Q8: Protecting your mouth from drying out, Q9: Providing whole mouth comfort, Q10: Helping you to swallow without difficulty, Q11: Helping mouth feel 'normal', Q12: Having a cooling sensation. PPAQ I was assessed at 2 hours after supervised product use on Day 8 of treatment. | ITT (N= 396) population defined as all randomized participants with at least one post-baseline assessment of efficacy. The ITT population was analyzed as per randomized treatment. | Posted | Mean | Standard Deviation | Score on scale | At Day 8 (2 hours after supervised product use) |
|
|
|
| Secondary | Individual Questions Scores of Modified Product Performance and Attributes Questionnaire II (PPAQ II) | Participants were asked to use the following scale to rate questions of PPAQ II as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. PPAQ II had following questions; Q1: Providing relief all night, Q2: Reducing the number of times you wake up from dry mouth, Q3: Feeling less parched when you wake up, Q4: Having a long lasting dry mouth relief, Q5. Having a long lasting lubricating effect, Q6: Having a long lasting moisturizing effect. PPAQ II was assessed before supervised product use on Day 8 and 29 of treatment. | ITT (N= 396) population defined as all randomized participants with at least one post-baseline assessment of efficacy. The ITT population was analyzed as per randomized treatment. | Posted | Mean | Standard Deviation | Score on scale | At Day 8 and 29 |
|
|
|
| Secondary | Area Under Curve (AUC) up to 4 Hours After Treatment- Response of All Question of the Modified Product Performance and Attributes Questionnaire I (PPAQ I) | The AUC was calculated for the interval starting at the time of the 30 minute response and ending at the time of the last valid reading using the trapezoidal method on Day 1 and Day 29. AUC was calculated for the score of the individual question of PPAQ1. All the questions were scored using the following scale: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent. | ITT (N= 396) population defined as all randomized participants with at least one post-baseline assessment of efficacy. The ITT population was analyzed as per randomized treatment. | Posted | Mean | Standard Deviation | Scores on scale/seconds | At Day 1 and 29 |
|
|
|
| 0 |
| 101 |
| 0 |
| 101 |
| 17 |
| 101 |
| EG001 | Oral Rinse | All the participants in this arm used an Oral rinse as instructed under the supervision of trained site staff on their visits. | 0 | 98 | 1 | 98 | 21 | 98 |
| EG002 | Moisturizing Mouth Spray | All the participants in this arm used a moisturising mouth spray as instructed under the supervision of trained site staff on their visits. | 0 | 98 | 2 | 98 | 12 | 98 |
| EG003 | Water Only Use | All the participants in this arm used water as instructed under the supervision of trained site staff on their visits. | 0 | 99 | 0 | 99 | 20 | 99 |
| DIVERTICULITIS | Infections and infestations | Systematic Assessment |
|
| OVARIAN CANCER | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| TRAUMATIC ULCER | Injury, poisoning and procedural complications | Systematic Assessment |
|
| TOOTH FRACTURE | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Tongue Injury | Injury, poisoning and procedural complications | Systematic Assessment |
|
| CONTUSION | Injury, poisoning and procedural complications | Systematic Assessment |
|
| FALL | Injury, poisoning and procedural complications | Systematic Assessment |
|
| MOUTH INJURY | Injury, poisoning and procedural complications | Systematic Assessment |
|
| THERMAL BURN | Injury, poisoning and procedural complications | Systematic Assessment |
|
| LIP INJURY | Injury, poisoning and procedural complications | Systematic Assessment |
|
| THROAT TIGHTNESS | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| COUGH | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| OROPHARYNGAL PAIN | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| ORAL HERPES | Infections and infestations | Systematic Assessment |
|
| BRONCHITIS | Infections and infestations | Systematic Assessment |
|
| NASOPHARYNGITIS | Infections and infestations | Systematic Assessment |
|
| HORDEOLUM | Infections and infestations | Systematic Assessment |
|
| TOOTH ABSCESS | Infections and infestations | Systematic Assessment |
|
| LARYNGITIS | Infections and infestations | Systematic Assessment |
|
| DEVICE EXPULSION | General disorders | Systematic Assessment |
|
| APPLICATION SITE ANAESTHESIA | General disorders | Systematic Assessment |
|
| PAIN | General disorders | Systematic Assessment |
|
| PRODUCT TASTE ABNORMAL | General disorders | Systematic Assessment |
|
| APPLICATION SITE PAIN | General disorders | Systematic Assessment |
|
| DEVICE FAILURE | General disorders | Systematic Assessment |
|
| PARAESTHESIA ORAL | Gastrointestinal disorders | Systematic Assessment |
|
| MOUTH HAEMORRHAGE | Gastrointestinal disorders | Systematic Assessment |
|
| LIP DRY | Gastrointestinal disorders | Systematic Assessment |
|
| CHEILITIS | Gastrointestinal disorders | Systematic Assessment |
|
| NAUSEA | Gastrointestinal disorders | Systematic Assessment |
|
| LIP EXFOLIATION | Gastrointestinal disorders | Systematic Assessment |
|
| GINGIVAL PAIN | Gastrointestinal disorders | Systematic Assessment |
|
| ABDOMINAL DISCOMFORT | Gastrointestinal disorders | Systematic Assessment |
|
| DRY MOUTH | Gastrointestinal disorders | Systematic Assessment |
|
| GLOSSODYNIA | Gastrointestinal disorders | Systematic Assessment |
|
| GINGIVAL INFLAMMATION | Gastrointestinal disorders | Systematic Assessment |
|
| TONGUE COATED | Gastrointestinal disorders | Systematic Assessment |
|
| HYPOAESTHESIA ORAL | Gastrointestinal disorders | Systematic Assessment |
|
| TONGUE DISORDER | Gastrointestinal disorders | Systematic Assessment |
|
| ORAL MUCOSAL EXFOLIATION | Gastrointestinal disorders | Systematic Assessment |
|
| GINGIVAL BLEEDING | Gastrointestinal disorders | Systematic Assessment |
|
| LIP ULCERATION | Gastrointestinal disorders | Systematic Assessment |
|
| TOOTHACHE | Gastrointestinal disorders | Systematic Assessment |
|
| HYPERTENSION | Vascular disorders | Systematic Assessment |
|
| MUSCULOSKELETAL PAIN | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
| Ions |
| D004573 | Electrolytes |
| D010087 | Oxides |
| D017601 | Oxygen Compounds |
|
| At 1 hour |
|
|
| At 4 hours |
|
|
|
| At 1 hour |
|
|
| At 2 hours |
|
|
| At 4 hours |
|
|
|
| Q2 at Day 1, 1 hour |
|
|
| Q2 at Day 1, 2 hours |
|
|
| Q2 at Day 1, 4 hours |
|
|
| Q2 at Day 29, 30 minutes |
|
|
| Q2 at Day 29, 1 hour |
|
|
| Q2 at Day 29. 2 hours |
|
|
| Q2 at Day 29, 4 hours |
|
|
| Q3 at Day 1, 30 minutes |
|
|
| Q3 at Day 1, 1 hour |
|
|
| Q3 at Day 1, 2 hours |
|
|
| Q3 at Day 1, 4 hours |
|
|
| Q3 at Day 29, 30 minutes |
|
|
| Q3 at Day 29, 1 hour |
|
|
| Q3 at Day 29. 2 hours |
|
|
| Q3 at Day 29, 4 hours |
|
|
| Q4 at Day 1, 30 minutes |
|
|
| Q4 at Day 1, 1 hour |
|
|
| Q4 at Day 1, 2 hours |
|
|
| Q4 at Day 1, 4 hours |
|
|
| Q4 at Day 29, 30 minutes |
|
|
| Q4 at Day 29, 1 hour |
|
|
| Q4 at Day 29. 2 hours |
|
|
| Q4 at Day 29, 4 hours |
|
|
| Q5 at Day 1, 30 minutes |
|
|
| Q5 at Day 1, 1 hour |
|
|
| Q5 at Day 1, 2 hours |
|
|
| Q5 at Day 1, 4 hours |
|
|
| Q5 at Day 29, 30 minutes |
|
|
| Q5 at Day 29, 1 hour |
|
|
| Q5 at Day 29. 2 hours |
|
|
| Q5 at Day 29, 4 hours |
|
|
| Q6 at Day 1, 30 minutes |
|
|
| Q6 at Day 1, 1 hour |
|
|
| Q6 at Day 1, 2 hours |
|
|
| Q6 at Day 1, 4 hours |
|
|
| Q6 at Day 29, 30 minutes |
|
|
| Q6 at Day 29, 1 hour |
|
|
| Q6 at Day 29. 2 hours |
|
|
| Q6 at Day 29, 4 hours |
|
|
| Q7 at Day 1, 30 minutes |
|
|
| Q7 at Day 1, 1 hour |
|
|
| Q7 at Day 1, 2 hours |
|
|
| Q7 at Day 1, 4 hours |
|
|
| Q7 at Day 29, 30 minutes |
|
|
| Q7 at Day 29, 1 hour |
|
|
| Q7 at Day 29. 2 hours |
|
|
| Q7 at Day 29. 4 hours |
|
|
| Q8 at Day 1, 30 minutes |
|
|
| Q8 at Day 1, 1 hour |
|
|
| Q8 at Day 1, 2 hours |
|
|
| Q8 at Day 1, 4 hours |
|
|
| Q8 at Day 29, 30 minutes |
|
|
| Q8 at Day 29, 1 hour |
|
|
| Q8 at Day 29. 2 hours |
|
|
| Q8 at Day 29. 4 hours |
|
|
| Q9 at Day 1, 30 minutes |
|
|
| Q9 at Day 1, 1 hour |
|
|
| Q9 at Day 1, 2 hours |
|
|
| Q9 at Day 1, 4 hours |
|
|
| Q9 at Day 29, 30 minutes |
|
|
| Q9 at Day 29, 1 hour |
|
|
| Q9 at Day 29. 2 hours |
|
|
| Q9 at Day 29. 4 hours |
|
|
| Q10 at Day 1, 30 minutes |
|
|
| Q10 at Day 1, 1 hour |
|
|
| Q10 at Day 1, 2 hours |
|
|
| Q10 at Day 1, 4 hours |
|
|
| Q10 at Day 29, 30 minutes |
|
|
| Q10 at Day 29, 1 hour |
|
|
| Q10 at Day 29. 2 hours |
|
|
| Q10 at Day 29. 4 hours |
|
|
| Q11 at Day 1, 30 minutes |
|
|
| Q11 at Day 1, 1 hour |
|
|
| Q11 at Day 1, 2 hours |
|
|
| Q11 at Day 1, 4 hours |
|
|
| Q11 at Day 29, 30 minutes |
|
|
| Q11 at Day 29, 1 hour |
|
|
| Q11 at Day 29, 2 hours |
|
|
| Q11 at Day 29. 4 hours |
|
|
| Q12 at Day 1, 30 minutes |
|
|
| Q12 at Day 1, 1 hour |
|
|
| Q12 at Day 1, 2 hours |
|
|
| Q12 at Day 1, 4 hours |
|
|
| Q12 at Day 29, 30 minutes |
|
|
| Q12 at Day 29, 1 hour |
|
|
| Q12 at Day 29. 2 hours |
|
|
| Q12 at Day 29. 4 hours |
|
|
|
| Q2 at Day 8, 2 hours |
|
|
| Q3 at Day 8, 2 hours |
|
|
| Q4 at Day 8, 2 hours |
|
|
| Q5 at Day 8, 2 hours |
|
|
| Q6 at Day 8, 2 hours |
|
|
| Q7 at Day 8, 2 hours |
|
|
| Q8 at Day 8, 2 hours |
|
|
| Q9 at Day 8, 2 hours |
|
|
| Q10 at Day 8, 2 hours |
|
|
| Q11 at Day 8, 2 hours |
|
|
| Q12 at Day 8, 2 hours |
|
|
|
| Q1 at Day 29 |
|
|
| Q2 at Day 8 |
|
|
| Q2 at Day 29 |
|
|
| Q3 at Day 8 |
|
|
| Q3 at Day 29 |
|
|
| Q4 at Day 8 |
|
|
| Q4 at Day 29 |
|
|
| Q5 at Day 8 |
|
|
| Q5 at Day 29 |
|
|
| Q6 at Day 8 |
|
|
| Q6 at Day 29 |
|
|
|
| Q1, AUC At Day 29 |
|
|
| Q2, AUC At Day 1 |
|
|
| Q2, AUC At Day 29 |
|
|
| Q3, AUC At Day 1 |
|
|
| Q3, AUC At Day 29 |
|
|
| Q4, AUC At Day 1 |
|
|
| Q4, AUC At Day 29 |
|
|
| Q5, AUC At Day 1 |
|
|
| Q5, AUC At Day 29 |
|
|
| Q6, AUC At Day 1 |
|
|
| Q6, AUC At Day 29 |
|
|
| Q7, AUC At Day 1 |
|
|
| Q7, AUC At Day 29 |
|
|
| Q8, AUC At Day 1 |
|
|
| Q8, AUC At Day 29 |
|
|
| Q9, AUC At Day 1 |
|
|
| Q9, AUC At Day 29 |
|
|
| Q10, AUC At Day 1 |
|
|
| Q10, AUC At Day 29 |
|
|
| Q11, AUC At Day 1 |
|
|
| Q11, AUC At Day 29 |
|
|
| Q12, AUC At Day 1 |
|
|
| Q12, AUC At Day 29 |
|
|